“…These markers of AD currently include neurodegenerative metrics obtained from MRI (e.g., less GMV) and PET (e.g., abnormal amyloid and tau depositions; Jack et al, 2018 ). Potential future directions might be to combine the Frascati criteria with emerging neuroimaging markers of HAND, including GMV as demonstrated in the present study, as well as functional MRI ( Ances et al, 2009 , Nguchu et al, 2021 , Plessis et al, 2014 , Hall et al, 2021 , Minosse et al, 2021 ) and magnetoencephalography ( Spooner et al, 2020 , Lew et al, 2018 , Wiesman et al, 2018 , Wilson et al, 2017. , Becker et al, 2012a , Becker et al, 2012b ).…”